Rheumatoid__O arthritis__O is__O a__O persistent__O inflammatory__O arthritis__O of__O synovial__O joints__O that__O currently__O affects__O around__O 500,000__O people__O in__O England__B-LOC and__O an__O estimated__O 0.5-1%__O of__O the__O adult__O population__O worldwide.__O
Rheumatoid__O arthritis__O can__O lead__O to__O pain,__O deformity__O and__O loss__O of__O function,__O work__O disability,__O economic__O losses__O and__O premature__O death.__O
Prior__O to__O the__O development__O of__O anti-TNF&#945;__O therapies,__O a__O considerable__O proportion__O of__O patients__O treated__O with__O the__O available__O disease-modifying__O antirheumatic__O drugs__O (DMARDs)__B-ORG were__O still__O plagued__O by__O premature__O death__O rates,__O and__O had__O evidence__O of__O persistent__O disease__O activity,__O with__O many__O patients__O remaining__O wheelchair__O bound__O due__O to__O ongoing__O joint__O damage__O and__O disability.__O
The__O commercial__O introduction__O of__O anti-TNF&#945;__O agents__O from__O 1999__O has__O profoundly__O changed__O the__O management__O of__O severe__O rheumatoid__O arthritis__O throughout__O the__O developed__O world,__O with__O over__O 2__O million__O patients__O having__O received__O this__O treatment.__O
Anti-TNF&#945;__O therapy__O has__O had__O a__O profound__O impact__O on__O the__O quality__O of__O life__O of__O patients__O with__O rheumatoid__O arthritis.__O
It__O is__O capable__O of__O not__O only__O controlling__O symptoms__O such__O as__O pain__O and__O stiffness,__O it__O can__O also__O protect__O joints__O from__O the__O structural__O damage__O which__O leads__O to__O disability.__O
This__O has__O also__O prompted__O the__O successful__O use__O of__O anti-TNF&#945;__O therapy__O in__O a__O number__O of__O other__O immune-inflammatory__O diseases,__O such__O as__O juvenile__O rheumatoid__O arthritis,__O ankylosing__O spondylitis,__O psoriatic__O arthritis,__O Crohn's__B-MISC disease,__O ulcerative__O colitis,__O and__O psoriasis.__O
One__O study__O on__O the__O effects__O of__O anti-TNF&#945;__O therapy__O in__O patients__O with__O Crohn's__O disease__O showed__O that__O it__O significantly__O improved__O the__O quality__O of__O life__O of__O patients,__O by__O increasing__O their__O ability__O to__O work__O and__O participate__O in__O leisure__O activities,__O decreasing__O fatigue,__O depression,__O and__O anger7.__O
In__O addition,__O whilst__O TNF__B-ORG inhibition__O in__O established__O disease__O does__O not__O result__O in__O cure,__O evidence__O is__O emerging__O that__O commencing__O treatment__O during__O early__O disease__O can__O result__O in__O drug-free__O remission8.__O
The__O British__B-ORG Society__I-ORG of__I-ORG Rheumatology__I-ORG issued__O guidelines__O on__O the__O use__O of__O anti-TNF&#945;__O inhibitors__O in__O rheumatoid__O arthritis__O in__O 2001,__O and__O the__O National__B-ORG Institute__I-ORG for__I-ORG Health__I-ORG and__I-ORG Clinical__I-ORG Excellence__I-ORG endorsed__O the__O therapy__O in__O 20029.__O
The__O combination__O of__O an__O anti-TNF&#945;__O agent__O with__O methotrexate__O remains__O unsurpassed__O in__O reducing__O the__O signs__O and__O symptoms__O of__O rheumatoid__O arthritis__O and__O in__O improving__O joint__O destruction10.__O
Current__O UK__B-LOC guidelines__O also__O address__O the__O optimal__O use__O of__O biologics__O and__O disease__O modifying__O antirheumatic__O drugs__O (including__O methotrexate)__O for__O the__O management__O of__O rheumatoid__O arthritis11,__O 12.__O
The__O 2010__O European__B-ORG League__I-ORG Against__I-ORG Rheumatism__I-ORG guidelines__O for__O the__O management__O of__O rheumatoid__O arthritis__O recognise__O the__O importance__O of__O early__O introduction__O of__O biologic__O TNF&#945;__B-ORG inhibitors__O in__O patients__O failing__O to__O reach__O a__O treatment__O target__O of__O remission__O or__O low__O disease__O activity__O on__O conventional,__O non-biologic__O synthetic__O DMARDs13.__B-ORG
Anti-TNF&#945;__O therapy__O is__O the__O recommended__O first__O line__O treatment,__O and__O if__O therapeutic__O response__O is__O not__O achieved__O within__O 3-6__O months,__O the__O guidelines__O recommend__O a__O trial__O of__O either__O a__O second__O anti-TNF__O agent__O or__O a__O biologic__O of__O an__O alternative__O mechanism__O of__O action13.__O
The__O development__O of__O anti-TNF&#945;__O inhibitors__O by__O the__O Kennedy__B-ORG Institute__I-ORG has__O had__O a__O major__O impact__O on__O the__O pharmaceutical__O industry.__O
Sales__O of__O the__O five__O licensed__O anti-TNF&#945;__O inhibitors__O (Key__O Patents:__O US__B-LOC App__O 08/446,674__O /__O 20030064070A1;__O US__B-LOC App__O 20020136723A1;__O US__B-LOC App__O 20020010180A1)__O for__O all__O indications__O reached__O US$24.4__O billion__O in__O 201114,__O most__O of__O which__O was__O used__O for__O the__O treatment__O of__O rheumatoid__O arthritis.__O
Interest__O in__O the__O therapeutic__O use__O of__O biologics__O has__O blossomed__O since__O their__O discovery,__O with__O monoclonal__O antibodies__O making__O up__O around__O one-third__O of__O drugs__O in__O the__O sector,__O essentially__O all__O for__O chronic__O disease.__O
High__O unit__O production__O costs__O of__O monoclonal__O antibodies__O are__O falling__O as__O their__O use__O grows.__O
New__O products__O are__O now__O also__O being__O launched,__O including__O generic__O versions__O of__O the__O top__O selling__O antibodies__O as__O they__O lose__O patent__O protection,__O which__O should__O eventually__O benefit__O patients__O and__O society.__O
It__O is__O predicted__O that__O by__O 2014,__O three__O of__O the__O four__O top__O drugs__O sold__O worldwide__O will__O be__O anti-TNFs15,__B-MISC while__O the__O top__O 5__O will__O be__O biologics,__O monoclonal__O antibodies__O and__O antibody__O like__O fusion__O proteins.__O
This__O shows__O the__O outstanding__O impact__O of__O this__O research__O on__O the__O field__O of__O therapeutics15.__O
